The SCIENCE trial is a multicenter, open-label, randomized, parallel, noninferiority investigator-initiated trial (IIT). This study aims to evaluate the prognostic differences between selective mediastinal lymph node sampling and systematic mediastinal lymph node dissection in patients with node-negative stage IIA to IIIB (N2) non-small-cell lung cancer (NSCLC) undergoing anatomical lobectomy following neoadjuvant chemoimmunotherapy.
Voluntary participation with a signed written informed consent form.
Aged ≥ 18 and < 75 years, of either gender.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Anticipated life expectancy of ≥ 12 months.
Anticipated inability to tolerate an anatomical lobectomy;
Anticipated requirement for sleeve resection, pneumonectomy, or pulmonary autotransplantation to remove the affected lobe;
Prior thoracic radiotherapy before the initiation of surgical treatment;
History of allogeneic tissue or solid organ transplantation;
Wen-zhao ZHONG
Lead sponsor
Guangdong Provincial People's Hospital
Sponsor institution
Shanghai Junshi Bioscience Co., Ltd.
Collaborator